Auto Owners Insurance Co Sells 45,650 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Auto Owners Insurance Co decreased its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 67.1% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 22,350 shares of the medical equipment provider’s stock after selling 45,650 shares during the quarter. Auto Owners Insurance Co’s holdings in Zimmer Biomet were worth $2,039,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of ZBH. Columbia River Financial Group LLC bought a new position in shares of Zimmer Biomet during the first quarter valued at approximately $30,000. Washington Trust Advisors Inc. bought a new position in shares of Zimmer Biomet during the first quarter valued at approximately $30,000. Accent Capital Management LLC bought a new position in shares of Zimmer Biomet during the first quarter valued at approximately $35,000. Cullen Frost Bankers Inc. grew its stake in shares of Zimmer Biomet by 1,452.4% during the first quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical equipment provider’s stock valued at $37,000 after buying an additional 305 shares during the last quarter. Finally, Hilltop National Bank bought a new position in shares of Zimmer Biomet during the second quarter valued at approximately $42,000. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Down 1.9%

Shares of NYSE:ZBH opened at $101.18 on Wednesday. Zimmer Biomet Holdings, Inc. has a 52-week low of $89.22 and a 52-week high of $114.72. The stock has a market cap of $20.04 billion, a P/E ratio of 24.62, a price-to-earnings-growth ratio of 2.37 and a beta of 0.67. The business’s 50 day moving average is $101.81 and its 200 day moving average is $97.63. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.98 by $0.09. The company had revenue of $2.08 billion for the quarter, compared to analysts’ expectations of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.Zimmer Biomet’s revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.01 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is 23.36%.

Analyst Ratings Changes

A number of research analysts have recently commented on ZBH shares. Stifel Nicolaus upped their target price on Zimmer Biomet from $115.00 to $118.00 and gave the company a “buy” rating in a research note on Friday, September 19th. Royal Bank Of Canada set a $111.00 target price on Zimmer Biomet in a research note on Friday, October 10th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, October 8th. UBS Group increased their price objective on Zimmer Biomet from $91.00 to $96.00 and gave the stock a “sell” rating in a research note on Friday, August 8th. Finally, Evercore ISI dropped their price objective on Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $111.94.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the sale, the senior vice president owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. This trade represents a 18.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.70% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.